Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Rezolute, Inc. (NASDAQ:RZLT) have received an average rating of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.3750.

Several equities research analysts have recently weighed in on the stock. BTIG Research increased their target price on shares of Rezolute from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Guggenheim boosted their price target on Rezolute from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Wedbush upped their price objective on Rezolute from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Maxim Group increased their price objective on Rezolute from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Citizens Jmp upgraded Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price on the stock in a research note on Wednesday, June 3rd.

Hedge Funds Weigh In On Rezolute

A number of hedge funds and other institutional investors have recently bought and sold shares of RZLT. BNP Paribas Financial Markets acquired a new position in Rezolute in the 2nd quarter valued at $25,000. Russell Investments Group Ltd. purchased a new position in Rezolute during the third quarter worth about $61,000. Legal & General Group Plc acquired a new stake in Rezolute in the second quarter valued at about $32,000. Raymond James Financial Inc. acquired a new stake in Rezolute in the second quarter valued at about $46,000. Finally, ExodusPoint Capital Management LP acquired a new stake in Rezolute in the fourth quarter valued at about $25,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Price Performance

Shares of NASDAQ:RZLT opened at $4.99 on Friday. Rezolute has a 1-year low of $1.07 and a 1-year high of $11.46. The stock has a market cap of $480.50 million, a P/E ratio of -6.09 and a beta of 0.54. The firm has a fifty day moving average price of $4.40 and a 200 day moving average price of $3.57.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Sell-side analysts expect that Rezolute will post -0.69 EPS for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.